The Swiss life-sciences company said it expected accelerated sales growth in the fourth quarter on the back of the timing of ...

In this article, we are going to take a look at where Lonza Group AG (OTC:LZAGY) stands against the other tech based ...

Lonza has continued to adapt to the evolving ADC landscape, including the recent addition of a highly potent vial fill ...

BigHat Biosciences is adding Synaffix’s antibody-drug conjugate (ADC) tech to its wardrobe, pairing the science with its antibody design platform to tailor a next-gen ADC pipeline. | BigHat ...

The Dutch biotech Synaffix and the Swiss company BigHat Biosciences announced yesterday that they have entered into a ...

Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, announced today a long-term extension of its collaboration with a major global biopharmaceutical partner ...

(RTTNews) - Lonza Group (LZAGF.PK), a Swiss manufacturer focused on the pharmaceutical and nutrition businesses, on Thursday reported that its third-quarter performance was in line to deliver on ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

As Kate's personal feelings for Niko Lonza place others in danger, Laura's efforts to help an African American sailor on a layover in New York spark a dangerous attack.

Synaffix B.V. (“Synaffix”), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class ...

Lonza LONN-1.10%decrease; red down pointing triangle said it expected accelerated sales growth in the fourth quarter on the back of the timing of product releases and the ramp-up of its new ...

Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studiesCollaboration underscores Lonza's commitment to helping customers deliver ...